Viloxazine (Qelbree): A Faster Strattera?

On April 2, 2021, viloxazine, brand name Qelbree, received FDA approval for the treatment of ADHD in children and adolescents ages 6-17 years old. The latest issue of The Carlat Child Psychiatry Report includes a News of Note covering this newly approved medication for ADHD. In this podcast, we discuss the advantages and disadvantages of viloxazine for children and adolescents with ADHD.

https://www.thecarlatreport.com/podcast/viloxazine-qelbree-a-faster-strattera-2/

 

Author
Joshua Feder, M.D. Dr. Feder's Blog

You Might Also Enjoy...

Compassionate Leadership - 3 micro videos

As leaders we want to be kind while being effective, and this can be difficult. How do make sure that we do not become tired and angry but instead stay fresh and creative? Hear Zoe Kernohan Neely, Josh Feder MD & Jerri Lynn Hogg PhD in three mini videos.

Positive Development on Affect Autism

Positive Development is a start-up aiming to change the culture of the current state of autism treatment so that it opens the door for evidence-based developmental approaches for autism that are much more humane.

Three Approaches to Autism Intervention

We break down three main autism intervention approaches, and provide you with information that will help you improve on your abilities to recognize which particular autism intervention might be best for a specific patient.

Pharmacogenetics: Not Quite Ready for Prime Time?

There's so much marketing for genetic testing, but does it really help clinical care? Listen to our interview with Dr. Aaron Besterman about how genetic tests work, and what can be reliably taken away from them.